Drug and alcohol dependence reports · 2026
Wearable-derived measures of stress physiology in patients with opioid use disorder treated with methadone: A stress-task study in a real-world clinic with healthy controls.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Oesterle Tyler S, Xiao Yi, Bormann Nicholas L, Bergen-Cico Dessa K, Lai Benjamin, Sharma Harshit, Salekin Asif
Аннотация
BACKGROUND: Wearable biosensors enable real-time monitoring of physiological stress. While methadone maintenance treatment (MMT) is effective in opioid use disorder (OUD), inter-dose withdrawal and stress dysregulation remain challenges. We sought to identify wearable-derived digital biomarkers of stress in individuals with OUD receiving MMT.
METHODS: In this cross-sectional, laboratory-based study, 72 adults completed 76 sessions (14 OUD pre-methadone dose, 15 OUD post-dose, 47 healthy controls) of a standardized protocol of calm tasks (e.g., relaxing videos, positive memory recall) followed by stress-inducing tasks (e.g., horror video, mental arithmetic, negative memory recall). Physiological data were continuously recorded using the Empatica E4 wristband (heart rate, heart rate variability [HRV], electrodermal activity [EDA], skin temperature, accelerometry). Features were extracted using open-source toolkits. Linear mixed-effects models tested calm-stress differences and group effects; Random Forest classifiers evaluated calm versus stress classification.
RESULTS: Among 340 extracted features, 63 (18.5%) significantly differentiated calm from stress across all groups, with EDA- and accelerometry-derived features showing the most consistent stress sensitivity. Compared with controls, OUD participants demonstrated higher baseline arousal and altered stress reactivity, with the largest responses observed in the pre-dose group. Random Forest models performed best for cognitively demanding tasks (up to 98% accuracy) and more modestly for other tasks.
CONCLUSIONS: Wearable sensors can detect multidimensional alterations in resting-state physiology and stress reactivity among individuals with OUD on methadone. Future studies should validate these candidate biomarkers and test whether integrating wearable-derived stress detection into treatment improves clinically meaningful outcomes, such as stress management, craving, risk of return to opioid use, and retention.
METHODS: In this cross-sectional, laboratory-based study, 72 adults completed 76 sessions (14 OUD pre-methadone dose, 15 OUD post-dose, 47 healthy controls) of a standardized protocol of calm tasks (e.g., relaxing videos, positive memory recall) followed by stress-inducing tasks (e.g., horror video, mental arithmetic, negative memory recall). Physiological data were continuously recorded using the Empatica E4 wristband (heart rate, heart rate variability [HRV], electrodermal activity [EDA], skin temperature, accelerometry). Features were extracted using open-source toolkits. Linear mixed-effects models tested calm-stress differences and group effects; Random Forest classifiers evaluated calm versus stress classification.
RESULTS: Among 340 extracted features, 63 (18.5%) significantly differentiated calm from stress across all groups, with EDA- and accelerometry-derived features showing the most consistent stress sensitivity. Compared with controls, OUD participants demonstrated higher baseline arousal and altered stress reactivity, with the largest responses observed in the pre-dose group. Random Forest models performed best for cognitively demanding tasks (up to 98% accuracy) and more modestly for other tasks.
CONCLUSIONS: Wearable sensors can detect multidimensional alterations in resting-state physiology and stress reactivity among individuals with OUD on methadone. Future studies should validate these candidate biomarkers and test whether integrating wearable-derived stress detection into treatment improves clinically meaningful outcomes, such as stress management, craving, risk of return to opioid use, and retention.